Quick answer: MTHFR variants (C677T and A1298C) affect approximately 40–60% of the population and reduce the enzyme’s ability to convert folate to its active form (5-MTHF) by 35–70%. The consequence is impaired methylation — a process required for DNA repair, neurotransmitter synthesis, homocysteine clearance, and hormone metabolism. The fix is not complicated: bypass the MTHFR bottleneck with methylated B vitamins (methylfolate and methylcobalamin) rather than standard folic acid.
What MTHFR Is and Why It Matters
MTHFR stands for methylenetetrahydrofolate reductase — an enzyme encoded by the MTHFR gene on chromosome 1. Its job is to convert dietary folate and supplemental folic acid into 5-methyltetrahydrofolate (5-MTHF), the bioactive form of folate that enters the methylation cycle. This conversion step is rate-limiting: if MTHFR is functioning below capacity, the entire methylation cycle slows down regardless of how much folate you consume.
The methylation cycle is a biochemical pathway that adds or removes methyl groups (CH3) to DNA, proteins, neurotransmitters, hormones, and heavy metals to regulate their function. It runs approximately one billion times per second in every cell in the body. Key outputs of methylation include: SAM-e (the universal methyl donor), dopamine, serotonin, norepinephrine synthesis, homocysteine clearance, glutathione production (via the transsulfuration pathway), and DNA methylation patterns that regulate gene expression.
When methylation is impaired, the downstream consequences are broad and non-specific: elevated homocysteine (a cardiovascular and neurotoxic risk factor), reduced neurotransmitter synthesis capacity, impaired detoxification, and dysregulated gene expression. This is why MTHFR polymorphisms have been associated — though not causally established in all cases — with cardiovascular disease, pregnancy complications, depression, anxiety, autism spectrum disorder, and several cancers.
The Two Key MTHFR Variants: C677T and A1298C
Two polymorphisms account for most clinically relevant MTHFR dysfunction:
C677T (rs1801133): The most studied MTHFR variant. Named for the cytosine-to-thymine substitution at nucleotide position 677, it changes an alanine to a valine in the enzyme’s catalytic domain, reducing its thermostability and activity. Heterozygous carriers (one copy, written as “C/T” or “677CT”) have approximately 35% reduced MTHFR activity. Homozygous carriers (two copies, written as “T/T” or “677TT”) have 60–70% reduced activity. Population frequency: approximately 10–15% of people are homozygous T/T in European and North American populations; 40–45% are heterozygous C/T.
A1298C (rs1801131): An adenine-to-cytosine substitution at position 1298, changing a glutamate to an alanine in the regulatory domain. The A1298C variant has less impact on MTHFR activity in isolation (homozygous A1298C reduces activity by approximately 40%) but interacts synergistically with C677T. People who are compound heterozygous — one copy of each variant (677CT and 1298AC) — have activity comparable to homozygous 677TT, approximately 50–60% reduced.
The compound heterozygous pattern is the most clinically under-recognized. A patient who tests negative for C677T homozygosity may still have significant methylation impairment if they carry one copy of each variant. This is why testing for both polymorphisms simultaneously is essential — and why standard “MTHFR status” panels that only test C677T miss a substantial proportion of affected individuals.
The Folic Acid Problem: Why Standard Supplementation Can Make Things Worse
Here is the critical point that most practitioners and patients miss: synthetic folic acid (the form used in fortified foods and most supplements since mandatory fortification began in 1998) is not the same as methylfolate. Folic acid must be converted to 5-MTHF via DHFR and MTHFR enzymes before it can enter the methylation cycle. In people with MTHFR variants, this conversion is already impaired — so high-dose folic acid does not bypass the bottleneck. Instead, unconverted folic acid accumulates in blood (unmetabolized folic acid, or UMFA).
UMFA at elevated levels has demonstrated potential harms: it may compete with 5-MTHF for folate receptors (reducing effective delivery of the active form), impair natural killer cell cytotoxicity, and mask B12 deficiency by correcting the megaloblastic anemia component while leaving neurological damage to progress. A 2009 study by Morris et al. in PNAS found high serum folate combined with low B12 was associated with a significant increase in cognitive impairment and anemia risk in elderly subjects — worse than low folate alone.
For people with MTHFR variants, the correct intervention is 5-MTHF (methylfolate) — sold as Methylfolate, Deplin, or under brand names like Quatrefolic. This bypasses both the DHFR and MTHFR conversion steps and enters the methylation cycle directly. The typical dose is 400–1,000 mcg for heterozygous variants and 1,000–5,000 mcg for homozygous C677T or compound heterozygous, adjusted based on homocysteine response.
Homocysteine: The Functional Biomarker for Methylation Status
Homocysteine is the most clinically actionable biomarker for methylation dysfunction. Homocysteine is an intermediate amino acid produced when methionine donates its methyl group (becoming SAM-e, which becomes SAH, which becomes homocysteine). Under normal methylation conditions, homocysteine is rapidly recycled back to methionine via 5-MTHF and vitamin B12, or converted to cysteine and glutathione via the transsulfuration pathway (which requires B6).
When methylation is impaired — from MTHFR variants, B12 deficiency, B6 deficiency, or folate deficiency — homocysteine accumulates. Elevated homocysteine (above 10 μmol/L) is independently associated with cardiovascular disease: every 5 μmol/L increase in homocysteine increases cardiovascular event risk by approximately 20% (meta-analysis, Humphrey et al., AHRQ Evidence Report, 2008). Above 15 μmol/L is classified as hyperhomocysteinemia. Homocysteine is routinely included in comprehensive metabolic panels and can be ordered by any physician.
Target homocysteine: below 9 μmol/L for cardiovascular risk reduction; below 7 μmol/L is optimal. If your homocysteine is elevated, MTHFR status (plus B12 and folate levels) should be investigated. Conversely, if your homocysteine is normal, even homozygous MTHFR variants are being adequately compensated — and aggressive supplementation may not be needed.
The Methylation Protocol: What to Take and How Much
The core of any MTHFR support protocol is a methylated B-complex that bypasses the compromised conversion steps:
Methylfolate (5-MTHF), 400–5,000 mcg/day: The direct replacement for folic acid in MTHFR carriers. Start at 400–800 mcg and titrate up based on homocysteine response over 8–12 weeks. Some people with highly impaired MTHFR, very high homocysteine, or complex neurological symptoms require 5,000–15,000 mcg under physician guidance. Important caveat: people with COMT variants (another common polymorphism) may react poorly to high-dose methylfolate — symptoms including anxiety, irritability, and insomnia at doses above 1,000 mcg suggest COMT-related overmethylation and require dose reduction.
Methylcobalamin (B12), 1,000–5,000 mcg/day: As I discussed in detail in the B12 deficiency post, cyanocobalamin — the standard B12 supplement form — requires conversion to methylcobalamin and adenosylcobalamin to be active. MTHFR carriers with compromised methylation may have impaired cobalamin remethylation. Methylcobalamin bypasses this step. Sublingual delivery (dissolving under the tongue) achieves comparable serum levels to intramuscular injection for most people and is sufficient to correct functional B12 deficiency.
Pyridoxal-5-phosphate (P5P, active B6), 25–100 mg/day: B6 is the cofactor for the transsulfuration pathway — the alternative route for homocysteine disposal via cystathionine beta-synthase (CBS). This pathway converts homocysteine to cystathionine, then to cysteine, then ultimately to glutathione. Optimizing the transsulfuration pathway provides a second route for homocysteine clearance independent of MTHFR. P5P is the active form; pyridoxine (standard B6) requires conversion and may be less effective in people with compromised conversion.
Riboflavin (B2), 25–400 mg/day (for C677T homozygotes specifically): MTHFR is a riboflavin-dependent enzyme — FAD (flavin adenine dinucleotide, derived from B2) is an essential cofactor for MTHFR activity. A landmark trial by McNulty et al. (2006, Circulation) found high-dose riboflavin supplementation (1.6 mg/day, which is modest) significantly lowered homocysteine specifically in C677T homozygotes — reducing it by approximately 22% — without benefit in non-carriers. This suggests that partial MTHFR dysfunction in C677T TT genotypes is partly riboflavin-remediable, distinct from the methylfolate supplementation approach.
Trimethylglycine (TMG / betaine), 500–3,000 mg/day: TMG remethylates homocysteine to methionine via the BHMT (betaine-homocysteine methyltransferase) pathway — completely independent of MTHFR, folate, and B12. This alternative remethylation pathway is active primarily in the liver and kidney and provides important backup capacity when the main folate-dependent cycle is impaired. Studies show TMG reduces homocysteine by 1–4 μmol/L depending on baseline. It is also a liver-supportive compound (NAFLD treatment) and performance-relevant (TMG has been shown to modestly increase endurance and power output in several athletic studies).
MTHFR and Mental Health: The Neurotransmitter Connection
Methylation is required for the synthesis of dopamine, serotonin, norepinephrine, and melatonin via the COMT, MAOA, and AADC enzyme cascades that depend on SAM-e as a methyl donor. When methylation is impaired, neurotransmitter production and degradation are both affected. This biochemical connection underlies the observed (though still debated) association between MTHFR variants and depression, anxiety, and schizophrenia in epidemiological studies.
A 2012 meta-analysis in Molecular Psychiatry found C677T TT homozygosity was associated with a 36% increased risk of depression. This association is not causal evidence — people with MTHFR variants who maintain optimal methylation status (normal homocysteine, adequate methylfolate and B12 intake) do not appear to have elevated depression risk. The connection is mediated by functional methylation impairment, not the genetic variant itself.
Practically: if you have a C677T or compound heterozygous MTHFR variant and experience depression or anxiety that has not responded adequately to standard treatment, testing homocysteine and adding methylated B vitamins is a low-risk, evidence-supported adjunct. Some patients report significant improvement in mood and energy within 2–4 weeks of starting methylfolate — though responses vary considerably, likely due to the COMT interaction described above.
MTHFR and Pregnancy: Critical Considerations
Neural tube defects (NTDs) — spina bifida, anencephaly — are caused by failure of the neural tube to close in the first 28 days of gestation, often before a pregnancy is confirmed. Folate status is the primary modifiable risk factor: adequate folate during periconception reduces NTD risk by 50–70%. For women with MTHFR variants, standard folic acid supplementation may be inadequate — particularly for C677T homozygotes, whose impaired conversion means standard doses produce lower 5-MTHF levels in red blood cells.
Multiple observational studies and retrospective analyses have found C677T TT homozygosity is significantly overrepresented in mothers of NTD-affected pregnancies, suggesting inadequate compensated methylation contributes to risk. Current recommendations from many functional medicine practitioners and some national bodies suggest women with known MTHFR variants take methylfolate (5-MTHF) rather than or in addition to standard folic acid during the periconceptional period. The European Food Safety Authority (EFSA) recognized 5-MTHF as an appropriate alternative to folic acid for NTD prevention.
Recurrent pregnancy loss (RPL) is another area where MTHFR testing is frequently ordered. The association between MTHFR variants and RPL is controversial — some meta-analyses find a significant association (particularly for C677T TT in the context of elevated homocysteine), others find no independent association after controlling for confounders. Given the minimal risk of methylated B vitamin supplementation and the potential benefit, most reproductive medicine specialists recommend optimizing methylation status in RPL patients regardless of MTHFR results.
How to Get Tested: MTHFR Genotyping vs. Functional Testing
There are two approaches to assessing MTHFR status: direct genotyping and functional biomarker testing.
MTHFR genotyping identifies your specific C677T and A1298C allele combination. It is available through most lab networks (LabCorp, Quest) and can be ordered by a physician, or accessed via consumer genomics (23andMe, AncestryDNA). The raw data from 23andMe includes MTHFR variants — third-party tools like Genetic Genie can parse the rsIDs (rs1801133 for C677T, rs1801131 for A1298C). Knowing your genotype tells you your theoretical enzymatic capacity reduction.
Functional testing — specifically homocysteine and plasma methylmalonic acid (MMA) — tells you whether impairment is actually occurring. This is arguably more actionable: a C677T TT homozygote with normal homocysteine (below 9) and adequate dietary methylfolate may require no intervention. A C/T heterozygote with homocysteine of 14 clearly needs optimization regardless of genotype. I recommend homocysteine as part of a comprehensive lab panel for anyone over 35. It is an inexpensive, highly informative test that the conventional medical system largely ignores.
The ideal test panel for comprehensive methylation assessment: MTHFR genotyping (C677T + A1298C), homocysteine, serum B12, red blood cell (RBC) folate (more reflective of tissue status than serum folate), plasma MMA (the most sensitive functional B12 marker), and B6 (plasma pyridoxal phosphate). This complete picture costs approximately $200–300 through direct-to-consumer labs and provides everything needed to personalize a methylation protocol.
The Bottom Line
MTHFR variants are common, consequential in the presence of functional methylation impairment, and straightforward to address. The key insight is that the genetic variant itself is not the problem — inadequate compensation is. With optimal methylfolate, methylcobalamin, P5P, riboflavin, and TMG supplementation, homocysteine can be normalized in virtually all MTHFR carriers, and the downstream risks associated with impaired methylation largely eliminated.
The starting point is always testing homocysteine. If it is above 10 μmol/L, optimize your methylated B-vitamin status regardless of whether you have run MTHFR genotyping. If you have known MTHFR variants, replace folic acid with methylfolate in any supplements you take — particularly if pregnant or planning pregnancy. And if you are experiencing symptoms that have been resistant to standard treatment (depression, fatigue, recurrent pregnancy loss), a comprehensive lab panel including functional methylation markers may reveal a correctable root cause. Call our office at (810) 206-1402 for a functional medicine consultation that includes full methylation pathway assessment.
Frequently Asked Questions
How common is MTHFR?
Very common. Approximately 40-60% of the population carries at least one MTHFR variant when both C677T and A1298C are counted. Approximately 10-15% of people of European descent are homozygous C677T (the highest-impact single variant). The compound heterozygous pattern (one copy of each variant) affects another 15-20%. Having an MTHFR variant does not mean you have a disease — it means you may need to optimize your methylated B-vitamin status.
What are the symptoms of MTHFR mutation?
There are no symptoms specific to MTHFR variants. The consequences of impaired methylation (when it occurs) are non-specific: fatigue, depression, anxiety, difficulty concentrating, elevated homocysteine, recurrent miscarriage, or increased cardiovascular risk. These are also common symptoms of B12 deficiency, B6 deficiency, and hypothyroidism. Testing homocysteine and methylation biomarkers is the only way to determine whether MTHFR variants are causing functional impairment in a specific individual.
Should I avoid folic acid if I have MTHFR?
If you have a C677T homozygous or compound heterozygous MTHFR variant, replacing standard folic acid with methylfolate (5-MTHF) is a reasonable and well-supported approach. Avoiding all folate-containing foods is not appropriate — naturally occurring food folate (from leafy greens, legumes, liver) is partly in the form of polyglutamate folates that partially bypass the MTHFR step. The specific concern is synthetic folic acid from supplements and fortified foods, which requires full MTHFR conversion.
Can MTHFR cause anxiety?
MTHFR variants may contribute to anxiety by reducing SAM-e availability (which is needed for catecholamine degradation via COMT) and potentially altering serotonin/dopamine balance. However, this is indirect and mediated by functional methylation status. More commonly, high-dose methylfolate supplementation in people with COMT variants can cause anxiety by overmethylation — paradoxically worsening anxiety in some patients who start too high. Start at 400-800 mcg and increase slowly, monitoring for symptoms.
Dive Deeper
- MTHFR Gene Mutation: What It Means and the Methylation Protocol That Works
- MTHFR and Methylation: What the Gene Variant Means and How to Optimize Your Protocol
- Methylation and MTHFR Protocol: The Complete Guide to Optimizing Your Methylation Cycle
- Estrogen Metabolism: Phase 1 Pathways, COMT Methylation, and the Complete Protocol
- MTHFR Gene Variants: What They Mean, Testing, and the Complete Methylation Protocol